New melanoma cases in the United States are projected to rise 10.6 percent in 2026, according to American Cancer Society estimates that feed into federal cancer surveillance data. That increase is arriving alongside federal survey results showing that the vast majority of American adults do not consistently apply sunscreen, even during extended outdoor exposure on sunny days. The collision of rising incidence projections and flat prevention behavior creates a gap that could widen further if nothing changes in the next several years.
Federal Surveys and Rising Melanoma Cases on a Collision Course
The 10.6 percent projected increase draws on modeling methods published in the peer-reviewed Cancer Statistics, 2026 report in CA: A Cancer Journal for Clinicians. That paper uses observed incidence from central cancer registries and applies statistical trend analysis to generate annual case and death estimates. The National Cancer Institute reproduces these American Cancer Society projections in its own melanoma statistics, giving the figures a second layer of institutional backing and a consistent reference point for clinicians and policymakers.
On the behavior side, the numbers are blunt. In 2020, just 12.3 percent of men and 29.0 percent of women told National Health Interview Survey interviewers that they “always” use sunscreen when outside on a sunny day for more than one hour, according to a CDC Morbidity and Mortality Weekly Report analysis. Those figures describe a narrow scenario, not daily use in all conditions, yet even under that limited definition most adults reported inconsistent or zero protection.
A more recent federal data collection effort, the NCHS Rapid Surveys System, gathered sunscreen behavior data in August 2023. That round confirmed patterns of irregular use, though its dashboard does not yet offer the same long-running trend line that NHIS provides. Together, the two survey programs establish that low adherence is not a single-year anomaly but a durable pattern tracked across multiple federal instruments.
Registry Data, Projection Methods, and What the Numbers Actually Measure
Melanoma holds a distinct position in cancer tracking. Central cancer registries collect melanoma diagnoses, while basal cell and squamous cell carcinomas typically are not captured, according to CDC skin cancer statistics. That means melanoma projections rest on a more complete data foundation than estimates for other skin cancers, but it also means the full burden of UV-related skin disease is invisible in registry counts. When readers see a rising melanoma curve, they are looking at only one slice of a broader UV exposure problem.
The ACS projection methodology relies on Joinpoint regression to identify trend inflection points in observed incidence, paired with survival measures drawn from SEER’s analytical tools. These methods are well established in cancer epidemiology, but they project from past patterns rather than from a causal model that directly links sunscreen use to case counts. No primary registry record ties individual sunscreen non-use to the 10.6 percent rise. The connection between behavior surveys and incidence projections is an inference supported by decades of UV-exposure research, not a direct measurement within the same dataset.
That distinction matters because it sets the ceiling on what anyone can claim right now. The ACS projections tell us where case counts are heading based on historical trajectory. The CDC surveys tell us that protective behavior remains low. Bridging those two facts into a single causal statement requires longitudinal data linking individual behavior to individual outcomes, and that linked dataset does not exist in the public record. Instead, researchers are working with parallel streams: one describing how many people are diagnosed, the other describing how people say they behave in the sun.
Gaps in the Evidence and What to Watch Next
Several open questions limit how far the current data can take readers. The NHIS documentation shows that sunscreen questions have appeared in various survey years with slightly different wording and response options, making strict year-over-year comparison difficult. Small shifts in phrasing can nudge respondents toward different answers, complicating attempts to declare a precise trend in sunscreen adherence over time.
The August 2023 Rapid Surveys System collection used its own instrument, adding a fresh data point but also a new measurement context that does not map one-to-one onto earlier NHIS rounds. Analysts can say that both systems point toward inconsistent sunscreen use, but they cannot yet quantify how much behavior has changed between 2020 and 2023 with the same confidence they apply to cancer registry trends.
The ACS projection for 2026 is itself a modeled estimate, not a count of diagnosed cases. Actual 2025 and 2026 incidence data from SEER registries will not be finalized for roughly two to three years, given standard reporting lags. Until those observed numbers arrive, the 10.6 percent figure remains a statistical forecast, not a confirmed outcome. If future registry data come in below the projection, that could signal real progress in prevention or early detection; if they exceed it, the current models may be underestimating risk.
A testable question sits at the center of this story: if sunscreen adherence stays as low as successive federal surveys have documented, SEER staging data for 2027 and 2028 should show a measurable uptick in late-stage melanoma diagnoses, independent of population aging. That signal would strengthen the case that prevention failures are translating into clinical consequences. Conversely, if stage at diagnosis continues to shift earlier despite flat self-reported sunscreen use, other factors-such as increased skin checks or changing UV exposure patterns-may be offsetting the behavioral gap.
Researchers will also be watching for geographic and demographic patterns. Melanoma incidence varies by region, skin type, occupation, and access to dermatologic care. If projected increases concentrate in areas where survey data show particularly low sunscreen use or limited shade and protective clothing, that alignment would add circumstantial support to the behavioral hypothesis. But without individual-level linkage, those patterns will remain suggestive rather than definitive.
What the Numbers Mean for Everyday Decisions
For anyone spending time outdoors this summer, the practical takeaway is direct. Federal data show that most adults are not using sunscreen consistently even in the most obvious risk scenario: more than an hour of sun exposure on a clear day. Melanoma is one of the few cancers where a low-cost daily habit-limiting midday sun, wearing protective clothing, and applying broad-spectrum sunscreen-can reduce exposure to a well-established carcinogen.
Those individual choices will not show up in cancer registries for years, and no single person’s behavior will bend a national incidence curve on its own. But the gap between rising melanoma projections and stubbornly low sunscreen use suggests that many Americans are leaving an accessible form of protection on the table. Until future registry data clarify how much that gap is shaping actual case counts, the safest course is to treat UV exposure as a modifiable risk and act accordingly, even if the statistics have not yet caught up with today’s decisions.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
